CCTG Genitourinary Disease Site Committee welcomes new chair and modality sub-chairs

CCTG Genitourinary Disease Site Committee welcomes new chair and modality sub-chairs

The CCTG Genitourinary Disease Site Committee is very honoured to welcome the new chair and modality sub-chairs.

Dr. Sebastien Hotte incoming Chair & Medical Oncology Sub-Chair

CCTG GU Committee Chair Dr Sebastien HotteDr. Hotte is currently an Associate Professor in the Department of Oncology of McMaster University and is a staff oncologist at the Juravinski Cancer Centre. One of his main research interests is in Developmental Therapeutics and Phase I trials with clinical research interests in genito-urinary malignancies and is active in the field of translational research. He is the principle or co-author of over 130 peer-reviewed articles and over 220 original abstracts but first and foremost he is a husband and the proud father of two exceptional children, as well as a road cycling weekend warrior and Zwifter.



Dr. Wassim Kassouf & Dr. Tamim Niazi GU modality sub-chairs

CCTG would also like to announce Dr. Wassim Kassouf and Dr. Tamim Niazi as the incoming GU modality sub-chairs.

CCTG committe co-chair Wes KassoufDr. Wassim Kassouf is a Urologic Oncologist at the McGill University Health Center. He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 300 peer-review manuscripts and book chapters. Dr. Kassouf’s clinical practice focuses on all aspects of urologic oncology (including bladder, prostate, renal, and testes cancer) while his research focuses on bladder cancer.



CCTG Committe Co Chair Dr Tamim NiaziDr. Tamim Niazi is a Radiation Oncologist with the Department of Oncology, Division of Radiation Oncology at Jewish General Hospital. His research intrests include Intensity Modulated Radiotherapy (IMRT); High Dose Rate (HDR) Brachytherapy; Stereotactic Radiosurgery; Image Guided Radiotherapy (IGRT); Prostate Cancer and was a Clinical Trials Fellow at CCTG.

Dr. Niazi is also the co-chair for both the PR20 trial: A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer and the planned PR22 trial: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer.


Outgoing co-chairs Dr. Kim Chi & Dr. Neil Fleshner

CCTG would like to extend a sincere thank you to the outgoing co-chairs Dr. Kim Chi and Dr. Neil Fleshner for their many years (since 2013) of leadership with the GU Disease Site Committee. As co-chairs they led the committee in setting scientific and strategic objectives for genitourinary disease trials at CCTG and more broadly in clinical research in Canada.

DR Kim Chi CCTG outgoing Committee ChairDr. Kim Chi is a medical oncologist, a senior research scientist, professor of medicine at the University of British Columbia and recently named the head of BC Cancer. He is also the Co-Chair of the Genitourinary Disease Site for CCTG received national and international recognition for his contributions to prostate cancer research. Dr. Chi's research is focused in the area of genitourinary cancers with a special interest in prostate cancer and investigational new drugs. This includes phase I, II and III clinical trials, mechanisms of treatment resistance and predictive and prognostic biomarkers.

“I have been honoured to co-chair the GU Disease Site Committee. As a group, we have been able to lead innovative research and contribute to changes in the standard of care through clinical trials for the betterment of our patients - Dr Kim Chi”

Dr Fleshner CCTG Chair outgoing

Dr. Neil Fleshner is a surgeon and clinician scientist in the Division of Urology at the University Health Network and Princess Margaret Hospital where he holds the Love Chair in Prostate Cancer Prevention. Aside from surgical practice, Dr. Fleshner conducts research on urologic cancer prevention with an emphasis on prostate cancer. He has achieved international reputation as a talented cancer researcher who has made significant contributions in the field of urologic oncology. He has authored over 450 scientific papers and is an avid music lover and father of three.



CCTG Genitourinary Disease site committee page